STOCKHOLM, May 6, 2026 /PRNewswire/ — The Swedish Orphan Biovitrum AB (publ) (Sobi®) AGM was convened today on 6 May 2026. At the AGM, the shareholders, in accordance with the proposed resolutions, resolved as follows:
Adoption of the profit and loss statements and balance sheet and discharge of liability
The AGM adopted the income statements and the balance sheets and approved the proposal to carry forward the retained profits.
The Board members and the chief executive officer were discharged from liability for the financial year 2025.
Election of Board of Directors, remuneration to the Directors, election of Auditor and remuneration to the Auditor
Christophe Bourdon, Iris Loew-Friedrich, David Meek, Staffan Schüberg and Filippa Stenberg were re-elected as Board members and Mikael Dolsten and Åsa Riisberg were elected as new Board members for the period until the end of the next AGM. David Meek was re-elected as chair of the Board of Directors.
Ernst & Young AB was re-elected as auditor of Sobi for the period until the end of the next AGM.
The AGM approved the remuneration to the Board of Directors and the Auditor in accordance with the Nomination Committee’s proposal.
Remuneration report, long-term incentive programmes, authorisation for the Board of Directors to resolve on the issuance of new shares and/or convertible bonds and/or warrants, and transfer of own shares
The AGM resolved to approve the Board of Directors’ remuneration report.
The AGM resolved to approve the Board of Directors’ proposal to implement long-term incentive programmes, consisting of the following hedging arrangements in respect of the programmes. The All Employee Programme by way of a directed issue of no more than 223,677 series C shares, authorisation for the Board of Directors to resolve on a repurchase of all issued series C shares and transfer of no more than 170,200 own common shares to participants of the All Employee Programme. As regards the Management Programme the AGM resolved to approve the Board of Directors’ proposal regarding hedging arrangement by way of an equity swap agreement with a third party.
The AGM approved the Board of Directors’ proposal regarding the authorisation for the Board of Directors to resolve on the issuance of new shares and/or convertible bonds and/or warrants. The number of shares that may be issued, the number of shares that convertible bonds may be converted into and the number of shares that may be subscribed for by the exercise of warrants, may not exceed 39,710,000 shares in total.
The Board of Directors’ proposal regarding transfer of no more than 763,064 own common shares on the stock exchange for the purpose of covering certain payments, mainly social security contributions, that may occur in relation to the incentive programmes 2021, 2022 and 2023, was also approved by the AGM.
For full details on each proposal adopted by the AGM, please refer to sobi.com.
Sobi®
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 2,000 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
Gerard Tobin
Head of Investor Relations
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
|
Bulletin from Sobi’s Annual General Meeting (AGM) |
View original content:https://www.prnewswire.com/news-releases/bulletin-from-sobis-annual-general-meeting-agm-302764025.html
SOURCE Swedish Orphan Biovitrum AB
